No connection

Search Results

TLSIW

BEARISH
$0.85 Live
TriSalus Life Sciences, Inc. · NASDAQ
$0.8 52W Range $5.0
Overview AI Snowflake Price Valuation Profitability Growth Health Statements

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 21, 2026
Market cap
N/A
P/E
N/A
ROE
N/A
Profit margin
-86.9%
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
The deterministic health profile is critical, highlighted by a Piotroski F-Score of 1/9, indicating severe financial weakness. While the company shows strong top-line revenue growth of 59.8% and a high gross margin, these are offset by a devastating profit margin of -86.88% and negative shareholder equity (Price/Book of -1.26). Technical momentum is non-existent (0/100), with the stock trading near its 52-week low after a precipitous decline. Overall, the company exhibits the classic profile of a high-burn speculative entity in financial distress.

Key Strengths

Strong YoY revenue growth of 59.80%
High gross margin of 84.57%
Healthy current ratio of 2.80 indicating short-term liquidity
Strong quick ratio of 2.35
Significant Q/Q revenue growth of 59.85%

Key Risks

Severe financial instability indicated by Piotroski F-Score of 1/9
Negative shareholder equity as evidenced by Price/Book of -1.26
Extreme lack of profitability with a -86.88% profit margin
Catastrophic technical trend with 0/100 bullishness
High cash burn rate implied by -56.80% ROA

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
15
Weak
Value
5
Future
40
Past
20
Health
10
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score 1/9, Negative Price/Book, Severe technical downtrend, Deep operating losses
Confidence
90%
Value
5/100

P/B of -1.26 indicates the company's liabilities exceed its assets.

Positives
No standout positives identified.
Watchpoints
  • Negative Price/Book ratio
  • No P/E or Graham Number available due to lack of earnings
Future
40/100

Growth is present but currently unsustainable without a path to profitability.

Positives
  • Strong revenue growth (59.8%)
  • High gross margins
Watchpoints
  • Inability to convert revenue to profit
  • Negative operating margins
Past
20/100

Recent price action shows a complete collapse of investor confidence.

Positives
  • Historical 3Y growth was high
Watchpoints
  • 1Y change of -45.9%
  • Recent 1W change of -22.0%
Health
10/100

Despite short-term liquidity, the fundamental financial health is failing.

Positives
  • Current ratio > 2.0
Watchpoints
  • Piotroski F-Score 1/9
  • Negative ROA
Dividend
0/100

Dividend strength is 0/100.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No capacity for dividends

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.85

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for TLSIW and closest competitors.

Updated 2026-04-20
TLS
TriSalus Life Sciences, Inc.
Primary
5Y
-9.6%
3Y
+1600.0%
1Y
-45.9%
6M
-36.6%
1M
-22.7%
1W
-22.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
-1.26
P/S Ratio
N/A
EV/Revenue
N/A
EV/EBITDA
N/A
Market Cap
N/A

Profitability

Profit margins and return metrics

Profit Margin -86.88%
Operating Margin -24.77%
Gross Margin 84.57%
ROE N/A
ROA -56.8%

Growth

Revenue and earnings growth rates

Revenue Growth +59.8%
Earnings Growth N/A
Q/Q Revenue Growth +59.85%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
2.8
Strong
Quick Ratio
2.35
Excellent
Cash/Share
$0.33

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
86.7%
Op. Margin
-24.8%
Net Margin
-73.9%
Total Assets
$0.0B
Liabilities
$0.1B
Equity
$-0.0B
Debt/Equity
-2.04x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
102%

Past News Coverage

Recent headlines mentioning TLSIW from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile